Lingkang Pharmaceutical (603669.SH) released its report for the first quarter of 2024. The group achieved operating revenue during the period...
According to Zhitong Finance App News, Lingkang Pharmaceutical (603669.SH) released its report for the first quarter of 2024. The group achieved operating income of 76.8616 million yuan, an increase of 4.85% over the previous year; a net loss attributable to shareholders of listed companies of 1,60415 million yuan; a net loss of 204.198 million yuan attributable to shareholders of listed companies after deducting non-recurring profits and losses; and a basic loss of 0.02 yuan/share per share.